ZERBAXA is indicated for the treatment of adult and pediatric patients (birth to less than 18 years old) with complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, <\/em>and Pseudomonas aeruginosa.<\/em><\/p>\n\n\n ZERBAXA used in combination with metronidazole is indicated for the treatment of adult and pediatric patients (birth to less than 18 years old) with complicated intra-abdominal infections (cIAI) caused by the following susceptible Gram-negative and Gram-positive microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, <\/em>and Streptococcus salivarius.<\/em><\/p>\n\n\n To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.<\/p>\n\n<\/div><\/details><\/div>\n\n\n\n Renal dosing adjustments for adult patients (18 years and older) with HABP\/VABP per estimated CrCl (mL\/min)a,b<\/sup><\/p>\n\n\n
ZERBAXA\u00ae (ceftolozane and tazobactam) is indicated for the treatment of adult patients (18 years and older) with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP\/VABP), caused by the following susceptible Gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, <\/em>and Serratia marcescens.<\/em><\/p>\n\n\nUsage<\/strong><\/h3><\/div>\n\n\n
What is the recommended dosing for ZERBAXA when treating adult patients (18 years and older) with HABP\/VABP?<\/strong><\/h4><\/summary>
The recommended dose of ZERBAXA in adult patients 18 years and older with HABP\/VABP and creatinine clearance (CrCl)a<\/sup> greater than 50 mL\/min<\/span> is 3 grams<\/span> (two 1.5-g vials<\/span>) over 1-hour<\/span> period intravenously every 8 hours for 8 to 14 days. The duration of therapy should be guided by the severity and site of infection and the patient\u2019s clinical and bacteriological progress.<\/p>\n\n\n